Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab versus placebo in insulin-treated patients with diabetes and hypercholesterolemia at high cardiovascular risk
NL-OMON42569Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Alirocumab with Placebo (2 arms). Primary endpoints: Percent change in calculated LDL-cholesterol from baseline to Week 24 in the intent-to-treat population and Safety and tolerability. Started Feb 2016; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON42569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42569.